Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $68.19 USD
Change Today -3.03 / -4.25%
Volume 1.6M
ALKS On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 4:30 PM 03/6/15 All times are local (Market data is delayed by at least 15 minutes).

alkermes plc (ALKS) Snapshot

Open
$70.90
Previous Close
$71.22
Day High
$71.00
Day Low
$68.02
52 Week High
03/5/15 - $75.17
52 Week Low
10/13/14 - $38.49
Market Cap
10.1B
Average Volume 10 Days
2.2M
EPS TTM
$-0.60
Shares Outstanding
148.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ALKERMES PLC (ALKS)

alkermes plc (ALKS) Related Businessweek News

View More BusinessWeek News

alkermes plc (ALKS) Details

Alkermes Public Limited Company, an integrated biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in various therapeutic areas. The company offers RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA to treat schizophrenia schizoaffective disorder; AMPYRA/FAMPYRA to treat multiple sclerosis; BYDUREON to treat type II diabetes; and VIVITROL for alcohol and opioid dependence. It is also developing Aripiprazole Lauroxil for the treatment of schizophrenia; ALKS 5461 that is under Phase III study for the treatment of depressive disorder; ALKS 3831, a Phase II study medicine to treat schizophrenia; ALKS 8700, a monomethyl fumarate molecule, which is under Phase I study to treat multiple sclerosis; ALKS 7106, a drug candidate to treat pain with intrinsically low potential for abuse and overdose death; and RDB 1419, a proprietary investigational biologic cancer immunotherapy product that is under pre-clinical stage. The company serves pharmaceutical wholesalers, specialty pharmacies, and specialty distributors directly through its sales force. It has collaboration agreements with Janssen Pharmaceutica, NV; AstraZeneca plc; Acorda Therapeutics, Inc.; and other collaboration partners. Alkermes Public Limited Company was founded in 1987 and is headquartered in Dublin, Ireland.

1,300 Employees
Last Reported Date: 02/24/15
Founded in 1987

alkermes plc (ALKS) Top Compensated Officers

Chairman of the Board and Chief Executive Off...
Total Annual Compensation: $810.2K
President
Total Annual Compensation: $579.9K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $444.1K
Chief Legal Officer, Chief Compliance Officer...
Total Annual Compensation: $435.5K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $435.5K
Compensation as of Fiscal Year 2013.

alkermes plc (ALKS) Key Developments

Alkermes plc Announces New Drug Candidate, ALKS 7119 for Treatment of Alzheimer’s Agitation, Depression and Other CNS Diseases

Alkermes plc announced a new drug candidate, ALKS 7119, for the treatment of agitation in patients with Alzheimer’s disease, major depressive disorder (MDD) and other central nervous system (CNS) indications. Alkermes has successfully completed preclinical development and expects to initiate the first clinical study of ALKS 7119 in the third quarter of 2015. Additional details about ALKS 7119 will be presented at an Analyst and Investor Event hosted by Alkermes on March 2, 2015 afternoon. At the event, the company will also provide an update and outline the commercial opportunity for four late-stage product candidates in its emerging blockbuster portfolio addressing major chronic CNS diseases –– aripiprazole lauroxil for schizophrenia, ALKS 5461 for MDD, ALKS 3831 for schizophrenia and ALKS 8700 for multiple sclerosis. ALKS 7119 is the newest candidate in Alkermes’ pipeline of novel medicines for CNS diseases. ALKS 7119 has a multivalent mechanism of action that acts on key receptors in the brain involved in several CNS diseases, including agitation in patients with Alzheimer’s disease, MDD and others. Alkermes intends to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) in the second quarter and begin clinical trials in the third quarter of 2015. A number of patent applications have been submitted to the U.S. Patent and Trademark Office related to ALKS 7119. In addition to presenting information on ALKS 7119, the company will provide details on its late-stage pipeline candidates at the Analyst and Investor Event. Management will also present current epidemiologic data and discuss financial tools that may be useful in analyzing the economic value of the company’s late-stage product candidates.

Alkermes plc Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Earnings Guidance for the Year of 2015

Alkermes plc announced unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported total revenues of $175,161,000 against $154,478,000 a year ago. Operating loss was $15,688,000 against operating income of $5,843,000 a year ago. Income before income taxes was $40,780,000 against $2,874,000 a year ago. Net Income – GAAP was $30,514,000 or $0.20 per diluted share against $18,077,000 or $0.12 per diluted share a year ago. Non-GAAP Net Income was $16,821,000 or $0.11 per diluted share against $39,864,000 or $0.27 per diluted share a year ago. Capital expenditures were $13,325,000 against $9,856,000 a year ago. Free cash flow was $3,496,000 against $30,008,000 a year ago. For the year, the company reported total revenues of $618,789,000 against $596,333,000 a year ago. Loss before income taxes was $14,029,000 against income before income taxes of $13,263,000 a year ago. Operating loss was $87,144,000 against operating income of $34,478,000 a year ago. Net loss – GAAP was $30,061,000 or $0.21 per diluted share against $20,648,000 or $0.14 per diluted share a year ago. Non-GAAP Net Income was $54,593,000 or $0.35 per diluted share against $170,737,000 or $1.19 per diluted share a year ago. Capital expenditures were $33,651,000 against $27,313,000 a year ago. Free cash flow was $20,942,000 against $143,424,000 a year ago. For the year of 2015, Capital expenditures expected to be $55.0 million. Depreciation expense expected to be $35.0 million. Amortization expense expected to be $65.0 million. The company expects total revenues to range from $640 million to $670 million. The company expects R&D expenses to range from $345 million to $365 million. The company expects net interest expense to range from $10 million to $15 million. The company expects a GAAP net loss in the range of $255 million to $285 million, or a basic and diluted loss per share of $1.70 to $1.90, based on a weighted average basic and diluted share count of approximately 150 million shares outstanding. The company expects a non-GAAP net loss in the range of $40 million to $60 million, and non-GAAP basic and diluted EPS to range from $0.27 to $0.40. The company expects a free cash outflow in the range of $95 million to $115 million.

Alkermes plc Announces Results from Phase 1 Study of ALKS 7106

Alkermes plc announced topline results from a phase 1 clinical study of ALKS 7106, a new molecule intended for the treatment of pain. The randomized, double-blind, placebo-controlled study was designed to evaluate the safety, tolerability and pharmacokinetics of single escalating doses of ALKS 7106 in 64 healthy adults. Data from the study showed that ALKS 7106 did not meet the companyâ s pre-specified criteria for advancing into phase 2 clinical trials. Based on this evaluation, Alkermes will not pursue further development of ALKS 7106. The company will continue its efforts in developing novel compounds for the treatment of pain with intrinsically low potential for overdose toxicity and abuse, and it will now concentrate its efforts on the development of back-up compounds. The development of new medicines for the treatment of pain with differentiated profiles from conventional pain medicines is a dedicated focus area for Alkermes, as leverage deep understanding of opioid chemistry and pharmacology to enable the modulation of key brain receptors. ALKS 7106 does not have the properties necessary to warrant testing of its pharmacologic hypothesis in further studies in patients with pain, so it will shift its efforts to the identification and development of other pain candidates from its R&D initiatives.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALKS:US $68.19 USD -3.03

ALKS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioMarin Pharmaceutical Inc $113.77 USD +0.27
Cosmo Pharmaceuticals SpA SFr.175.80 CHF -0.20
Lupin Ltd 1,838 INR 0.00
Pacira Pharmaceuticals Inc/DE $96.63 USD -1.77
Salix Pharmaceuticals Ltd $158.01 USD +0.57
View Industry Companies
 

Industry Analysis

ALKS

Industry Average

Valuation ALKS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 16.8x
Price/Book 7.5x
Price/Cash Flow 373.2x
TEV/Sales 15.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALKERMES PLC, please visit www.alkermes.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.